in the early 2000s , the grading of recommendations assessment , development and evaluation ( grade ) working group developed a framework in which the certainty in evidence was based on numerous factors and not solely on study design which challenges the pyramid concept.8 study design alone appears to be insufficient on its own as a surrogate for risk of bias . certain methodological limitations of a study , imprecision , inconsistency and indirectness , were factors independent from study design and can affect the quality of evidence derived from any study design . for example , a meta - analysis of rcts evaluating intensive glycaemic control in non - critically ill hospitalised patients showed a non - significant reduction in mortality ( relative risk of 0.95 ( 95% ci 0.72 to 1.25)9 ) . the quality of this evidence is rated down due to the methodological imitations of the trials and imprecision ( wide ci that includes substantial benefit and harm ) . hence , despite the fact of having five rcts , such evidence should not be rated high in any pyramid . the quality of evidence can also be rated up . for example , we are quite certain about the benefits of hip replacement in a patient with disabling hip osteoarthritis . although not tested in rcts , the quality of this evidence is rated up despite the study design ( non - randomised observational studies).10 
  therefore , the first modification to the pyramid is to change the straight lines separating study designs in the pyramid to wavy lines ( going up and down to reflect the grade approach of rating up and down based on the various domains of the quality of evidence ) . another challenge to the notion of having systematic reviews on the top of the evidence pyramid relates to the framework presented in the journal of the american medical association user 's guide on systematic reviews and meta - analysis . the guide presented a two - step approach in which the credibility of the process of a systematic review is evaluated first ( comprehensive literature search , rigorous study selection process , etc ) . if the systematic review was deemed sufficiently credible , then a second step takes place in which we evaluate the certainty in evidence  based on the grade approach.11 in other words , a meta - analysis of well - conducted rcts at low risk of bias can not be equated with a meta - analysis of observational studies at higher risk of bias . for example , a meta - analysis of 112 surgical case series showed that in patients with thoracic aortic transection , the mortality rate was significantly lower in patients who underwent endovascular repair , followed by open repair and non - operative management ( 9% , 19% and 46% , respectively , p<0.01 ) . clearly , this meta - analysis should not be on top of the pyramid similar to a meta - analysis of rcts . after all , the evidence remains consistent of non - randomised studies and likely subject to numerous confounders . therefore , the second modification to the pyramid is to remove systematic reviews from the top of the pyramid and use them as a lens through which other types of studies should be seen ( ie , appraised and applied ) . the systematic review ( the process of selecting the studies ) and meta - analysis ( the statistical aggregation that produces a single effect size ) are tools to consume and apply the evidence by stakeholders . changing how systematic reviews and meta - analyses are perceived by stakeholders ( patients , clinicians and stakeholders ) has important implications . for example , the american heart association considers evidence derived from meta - analyses to have a level  a ( ie , warrants the most confidence ) . a evidence could have been high , moderate , low or of very low quality.12 the quality of evidence drives the strength of recommendation , which is one of the last translational steps of research , most proximal to patient care . one of the limitations of all  pyramids and depictions of evidence hierarchy relates to the underpinning of such schemas . the construct of internal validity may have varying definitions , or be understood differently among evidence consumers . a limitation of considering systematic review and meta - analyses as tools to consume evidence may undermine their role in new discovery ( eg , identifying a new side effect that was not demonstrated in individual studies13 ) . ebm teachers can compare it to the existing pyramids to explain how certainty in the evidence ( also called quality of evidence ) is evaluated . it can be used to teach how evidence - based practitioners can appraise and apply systematic reviews in practice , and to demonstrate the evolution in ebm thinking and the modern understanding of certainty in evidence .
a pyramid has expressed the idea of hierarchy of medical evidence for so long , that not all evidence is the same . 
 systematic reviews and meta - analyses have been placed at the top of this pyramid for several good reasons . 
 however , there are several counterarguments to this placement . 
 we suggest another way of looking at the evidence - based medicine pyramid and explain how systematic reviews and meta - analyses are tools for consuming evidence  that is , appraising , synthesising and applying evidence .